Effect of food on the bioavailability of palbociclib
Tóm tắt
This phase I study estimated the effect of food on bioavailability of palbociclib (IBRANCE®), and a selective inhibitor of cyclin-dependent kinase 4/6 approved for oncology indications has pH-dependent solubility and high permeability. In this randomized, four-sequence, four-period crossover study, 28 healthy volunteers received a single 125-mg dose of palbociclib (free-base capsule) following an overnight fast or (1) after a high-fat/-calorie meal, (2) after a low-fat/-calorie meal, and (3) between two moderate-fat/standard-calorie meals. Pharmacokinetic samples were collected predose and serially ≤144 h postdose; palbociclib concentrations were measured using validated high-performance liquid chromatography tandem mass spectrometry. Pharmacokinetic data were analyzed using a noncompartmental approach based on a mixed-effects model. Median time to maximum concentration was 8 h for all conditions. Exposure (AUCinf and C
max) increased slightly in the fed versus fasted conditions; ratios (90% CIs) of the adjusted geometric mean relative to the fasted condition ranged from 111.8 (104.3–119.9%) to 120.6% (112.6–129.1%) for AUCinf and from 124.0 (108.4–141.9%) to 137.8% (120.6–157.5%) for C
max due mainly to three subjects with significantly lower exposure (low liers) in the fasted condition. Pharmacokinetic variability was reduced in the fed (AUCinf, 23–27%; C
max, 21–24%) versus fasted (AUCinf, 39%; C
max, 73%) conditions. In a supplemental analysis excluding the three low liers, food intake did not affect palbociclib exposure. Food intake modestly increased palbociclib exposure while greatly reducing pharmacokinetic variability. For subjects with normal absorption, food intake did not affect palbociclib exposure. Thus, palbociclib should be administered with food. ClinicalTrials.gov: NCT01904747.
Tài liệu tham khảo
Fry DW, Harvey PJ, Keller PR, Elliott WL, Meade M, Trachet E, Albassam M, Zheng X, Leopold WR, Pryer NK, Toogood PL (2004) Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Ther 3:1427–1438
Toogood PL, Harvey PJ, Repine JT, Sheehan DJ, VanderWel SN, Zhou H, Keller PR, McNamara DJ, Sherry D, Zhu T, Brodfuehrer J, Choi C, Barvian MR, Fry DW (2005) Discovery of a potent and selective inhibitor of cyclin-dependent kinase 4/6. J Med Chem 48:2388–2406. doi:10.1021/jm049354h
Saab R, Bills JL, Miceli AP, Anderson CM, Khoury JD, Fry DW, Navid F, Houghton PJ, Skapek SX (2006) Pharmacologic inhibition of cyclin-dependent kinase 4/6 activity arrests proliferation in myoblasts and rhabdomyosarcoma-derived cells. Mol Cancer Ther 5:1299–1308. doi:10.1158/1535-7163.MCT-05-0383
Rocca A, Farolfi A, Bravaccini S, Schirone A, Amadori D (2014) Palbociclib (PD 0332991) : targeting the cell cycle machinery in breast cancer. Expert Opin Pharmacother 15:407–420. doi:10.1517/14656566.2014.870555
Marzec M, Kasprzycka M, Lai R, Gladden AB, Wlodarski P, Tomczak E, Nowell P, Deprimo SE, Sadis S, Eck S, Schuster SJ, Diehl JA, Wasik MA (2006) Mantle cell lymphoma cells express predominantly cyclin D1a isoform and are highly sensitive to selective inhibition of CDK4 kinase activity. Blood 108:1744–1750. doi:10.1182/blood-2006-04-016634
Finn RS, Crown JP, Lang I, Boer K, Bondarenko IM, Kulyk SO, Ettl J, Patel R, Pinter T, Schmidt M, Shparyk Y, Thummala AR, Voytko NL, Fowst C, Huang X, Kim ST, Randolph S, Slamon DJ (2015) The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol 16:25–35
Cristofanilli M, Turner NC, Bondarenko I, Ro J, Im SA, Masuda N, Colleoni M, DeMichele A, Loi S, Verma S, Iwata H, Harbeck N, Zhang K, Theall KP, Jiang Y, Huang Bartlett C, Koehler M, Slamon DJ (2016) Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol 17:425–439
US Food and Drug Administration (2016) Palbociclib (IBRANCE Capsules). Available at: http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm487080.htm. Accessed December 27, 2016
Schwartz GK, LoRusso PM, Dickson MA, Randolph SS, Shaik MN, Wilner KD, Courtney R, O’Dwyer PJ (2011) Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (schedule 2/1). Br J Cancer 104:1862–1868. doi:10.1038/bjc.2011.177
Flaherty KT, Lorusso PM, DeMichele A, Abramson VG, Courtney R, Randolph SS, Shaik MN, Wilner KD, O’Dwyer PJ, Schwartz GK (2012) Phase I, dose-escalation trial of the oral cyclin-dependent kinase 4/6 inhibitor PD 0332991, administered using a 21-day schedule in patients with advanced cancer. Clin Cancer Res 18:568–576. doi:10.1158/1078-0432.CCR-11-0509
DeMichele A, Clark A, Tan KS, Heitjan DF, Gramlich K, Gallagher M, Lal P, Feldman M, Zhang P, Colameco C, Lewis D, Langer M, Goodman N, Domchek SM, Gogineni K, Rosen M, Fox KR, O’Dwyer P (2014) CDK 4/6 inhibitor palbociclib (PD0332991) in Rb + advanced breast cancer: phase II activity, safety and predictive biomarker assessment. Clin Cancer Res 21:995–1001. doi:10.1158/1078-0432.CCR-14-2258
Dickson MA, Tap WD, Keohan ML, D’Angelo SP, Gounder MM, Antonescu CR, Landa J, Qin LX, Rathbone DD, Condy MM, Ustoyev Y, Crago AM, Singer S, Schwartz GK (2013) Phase II trial of the CDK4 Inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma. J Clin Oncol 31:2024–2028. doi:10.1200/JCO.2012.46.5476
IBRANCE® (palbociclib) (Full Prescribing Information) (2016) Full Prescribing Information. Pfizer Inc, New York, NY
Ruggiero A, Cefalo MG, Coccia P, Mastrangelo S, Maurizi P, Riccardi R (2012) The role of diet on the clinical pharmacology of oral antineoplastic agents. Eur J Clin Pharmacol 68:115–122. doi:10.1007/s00228-011-1102-8
Sun W, Klamerus KJ, Yuhas LM, Pawlak S, Plotka A, O’Gorman M, Kosa M, Wang D (2015) Impact of acid-reducing agents (ARAS) on the pharmacokinetics of palbociclib, a weak base with ph-dependent solubility, under differing food intake conditions [abstract 315]. Eur J Cancer 51: S59–S60. doi:10.1016/S0959-8049(16)30180-0
Sun W, Klamerus KJ, Yuhas LM, Pawlak S, Plotka A, O’Gorman M, Kosa M, Wang D (2015) Impact of acid-reducing agents on the pharmacokinetics of palbociclib, a weak base with pH-dependent solubility, under different food intake conditions. Presented at: European Cancer Congress; September 25–29; Vienna, Austria
Morais JA, Lobato Mdo R (2010) The new European Medicines Agency guideline on the investigation of bioequivalence. Basic Clin Pharmacol Toxicol 106:221–225. doi:10.1111/j.1742-7843.2009.00518.x